Evidence map›Paper›PMID 37391038›Full record

ArticleJournal of advanced research2024

Synergistic effect of cold gas plasma and experimental drug exposure exhibits skin cancer toxicity in vitro and in vivo.

Lars Boeckmann, Julia Berner, Marcel Kordt, Elea Lenz, Mirijam Schäfer, Marie-Luise Semmler, Anna Frey, Sanjeev Kumar Sagwal, Henrike Rebl, Lea Miebach and 14 more

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Organoids in skin wound healing.Burns & trauma · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Beilstein journal of organic chemistry · 2024
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 1 country.

Lars BoeckmannClinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Center, 18057 Rostock, Germany. Electronic address: lars.boeckmann@med.uni-rostock.de.
Julia BernerDepartment of Oral, Maxillofacial, and Plastic Surgery, Greifswald University Medical Center, 17475 Greifswald, Germany; ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany.
Marcel KordtRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Elea LenzInstitute for Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
Mirijam SchäferClinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Center, 18057 Rostock, Germany.
Marie-Luise SemmlerClinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Center, 18057 Rostock, Germany.
Anna FreyInstitute for Chemistry, Rostock University, 18059 Rostock, Germany.
Sanjeev Kumar SagwalZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany.
Henrike ReblDepartment of Cell Biology, Rostock University Medical Center, 18057 Rostock, Germany.
Lea MiebachZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany.
Felix NiessnerZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany.
Marie SawadeDepartment of Cell Biology, Rostock University Medical Center, 18057 Rostock, Germany.
Martin HeinInstitute for Chemistry, Rostock University, 18059 Rostock, Germany.
Robert RamerInstitute for Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
Eberhard GrambowRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Christian SeebauerDepartment of Oral, Maxillofacial, and Plastic Surgery, Greifswald University Medical Center, 17475 Greifswald, Germany.
Thomas von WoedtkeZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany.
Barbara NebeDepartment of Cell Biology, Rostock University Medical Center, 18057 Rostock, Germany.
Hans-Robert MetelmannDepartment of Oral, Maxillofacial, and Plastic Surgery, Greifswald University Medical Center, 17475 Greifswald, Germany.
Peter LangerInstitute for Chemistry, Rostock University, 18059 Rostock, Germany.
Burkhard HinzInstitute for Pharmacology and Toxicology, Rostock University Medical Center, 18057 Rostock, Germany.
Brigitte VollmarRudolf-Zenker-Institute of Experimental Surgery, Rostock University Medical Center, 18057 Rostock, Germany.
Steffen EmmertClinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Center, 18057 Rostock, Germany. Electronic address: steffen.emmert@med.uni-rostock.de.
Sander BekeschusClinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Center, 18057 Rostock, Germany; ZIK plasmatis, Leibniz Institute for Plasma Science and Technology (INP), 17489 Greifswald, Germany. Electronic address: sander.bekeschus@inp-greifswald.de.
University of Rostock · DELeibniz Institute for Plasma Science and Technology · DEUniversitätsmedizin Greifswald · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSkin cancer is often fatal, which motivates new therapy avenues. Recent advances in cancer treatment are indicative of the importance of combination treatments in oncology. Previous studies have identified small molecule-based therapies and redox-based technologies, including photodynamic therapy or medical gas plasma, as promising candidates to target skin cancer.

objectiveWe aimed to identify effective combinations of experimental small molecules with cold gas plasma for therapy in dermato-oncology.

methodsPromising drug candidates were identified after screening an in-house 155-compound library using 3D skin cancer spheroids and high content imaging. Combination effects of selected drugs and cold gas plasma were investigated with respect to oxidative stress, invasion, and viability. Drugs that had combined well with cold gas plasma were further investigated in vascularized tumor organoids in ovo and a xenograft mouse melanoma model in vivo.

resultsThe two chromone derivatives Sm837 and IS112 enhanced cold gas plasma-induced oxidative stress, including histone 2A.X phosphorylation, and further reduced proliferation and skin cancer cell viability. Combination treatments of tumor organoids grown in ovo confirmed the principal anti-cancer effect of the selected drugs. While one of the two compounds exerted severe toxicity in vivo, the other (Sm837) resulted in a significant synergistic anti-tumor toxicity at good tolerability. Principal component analysis of protein phosphorylation profiles confirmed profound combination treatment effects in contrast to the monotherapies.

conclusionWe identified a novel compound that, combined with topical cold gas plasma-induced oxidative stress, represents a novel and promising treatment approach to target skin cancer.

Indexed as

Skin DiseasesSkin NeoplasmsAnimalsCombined Modality TherapyDisease Models, AnimalHistonesHumansMedical OncologyMiceHistonesMelanomaReactive oxygen speciesROSSCCSmall moleculesSquamous cell carcinoma

Identifiers

PMID37391038
PMCPMC10918357
OpenAlexW4382358073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.